Advancing mRNA vaccines; the need for improved delivery technologies
20Med’s mission is to establish a polymeric nanoparticles (PNP) platform that stands as a leading alternative to LNPs in the delivery of mRNA vaccines for seasonal influenza.
20Med PNP platform
At 20Med Therapeutics, we develop RNA and DNA based vaccines and therapeutics based on proprietary bio-responsive polymeric nanoparticles (PNPs).
In developing thermostable vaccines for infectious diseases, we aim to tackle the inequitable global distribution of medical innovations.
In addition, our polymeric nanoparticle platform is being applied to the development of several vaccines and therapeutics for human and animal health indications to help accelerate partnered programs toward clinical trials.
Our technology addresses the limitations of other delivery technologies
We offer distinct advantages:
Ease to manufacture – accessible starting materials, one step loading and formulation in absence of solvents, no purification step needed after formulation and therefore no loss of RNA/DNA.
Scalable and reproducible – different formulation volumes result in the same product. Functionality and size independent of operator and batch
Improved thermostability – loaded 20Med nanoparticles can be stored in solution at lower temperatures or at room temperature as a lyophilized product; partnership agreement with Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of our delivery technology in a project that aims to store the product at 2-8 degrees with no need for frozen storage.
Unique IP position – composition of matter patents granted worldwide; independent of complex IP landscape of lipid nanoparticles.
Strong immunogenicity - using 20Med PNPs could contribute to greater immunogenicity of mRNA and DNA vaccines